The matrix metalloproteinases (MMPs) constitute a family of multidomain zinc endopeptidases which contain a catalytic domain with a common metzincin-like topology. The MMPs are involved not only in extracellular matrix degradation, but also in a number of other biological processes. Normally, their proteolytic activity is regulated precisely by their main endogenous protein inhibitors, in particular the tissue inhibitors of metalloproteinases (TIMPs). Disruption of this balance results in serious diseases, such as arthritis, tumour growth and metastasis, rendering the MMPs attractive targets for inhibition therapy. Knowledge of their tertiary structures is crucial for a full understanding of their functional properties. Since the first publication of atomic MMP structures in 1994, much more structural information has become available on details of the catalytic domain, on its interaction with synthetic and protein inhibitors, on domain organization and on the formation of complexes with other proteins. This review will outline our current knowledge of MMP structure.
Introduction
The matrix metalloproteinases (MMPs; matrixins; EC 3.4.24.-) form a large family of structurally and functionally related zinc endopeptidases that are found in species from plants via hydra to humans [1, 2] . Collectively, the MMPs are capable of degrading, both in vitro and in vivo, all kinds of extracellular matrix protein components, such as interstitial and basement membrane collagens, proteoglycans, fibronectin and laminin, and are thus implicated in connective tissue remodelling processes associated with embryonic development, pregnancy, growth, wound healing, etc. Many of these MMPs, however, are also involved in the shedding and release of latent growth factors, cytokines and cell surface receptors, in the activation of proMMPs, and in the inactivation of proteinase and angiogenesis inhibitors, thus participating in diverse physio-logical processes (for a recent review, see [3] ). Normally, the degradative potential of the MMPs is held in check by the endogenous specific tissue inhibitors of metalloproteinases (TIMPs). Disruption of this MMP-TIMP balance can result in diseases such as rheumatoid arthritis, osteoarthritis, atherosclerosis, heart failure, fibrosis, pulmonary emphysema, tumour growth, and cell invasion and metastasis. The therapeutic inhibition of MMPs is a promising approach for the treatment of some of these diseases, and the MMP structures are therefore attractive targets for rational inhibitor design (for recent references, see [4] [5] [6] [7] ).
Due to their identical catalytic zinc environment, a characteristic methionine-containing tight turn below this catalytic zinc ion and the unique topology of their catalytic domain, the MMPs have been grouped in the 'metzincin' zinc endopeptidase superfamily [8, 9] . Vertebrate MMPs are synthesized as latent multidomain proteinases which are transported to the cell surface, where they either remain membrane-bound or are secreted into the extracellular space. Individual vertebrate MMPs have been named according to their presumed substrates or classified by sequential (mainly chronological) numbers, which run from MMP-1 to MMP-28 (omitting numbers [4] [5] [6] . The MMP gene family in humans encodes, besides three pseudogenes, 25 related proteinases, of which 22 have been well characterized (for details, see a recent review [10] ). These MMPs have counterparts in other mammals (such as mouse, rat, rabbit, pig, cattle and horse), in other vertebrates, in invertebrates and in plants (see [3, 11] ), which together form the MMP or matrixin subfamily A of the metalloproteinase M10 family in MEROPS clan MB [12] .
All of these MMPs are synthesized with an N-terminal signal sequence, which is removed upon insertion into the endoplasmic reticulum, yielding the latent proenzymes. All human proMMPs have in common an N-terminal prodomain of approx. 80 amino acids and an adjacent characteristic catalytic domain which consists of approx. 175 amino acid residues (see Figure 1) [except in MMP-2 (gelatinase A) and MMP-9 (gelatinase B), which have additional 175-residue fibronectin type II domain (FN) inserts]. In MMP-23 [13, 14] , the N-terminal part of the pro-domain seems to be modified into a transmembrane (TM) domain [15] . All other human MMP pro-domains contain a 'cysteine-switch' PRCXXPD consensus sequence [16] , whose unpaired cysteine blocks the catalytic zinc in the latent pro-form. In all human MMPs, the linker between the pro-domain and the catalytic domain is susceptible to proteolytic activation cleavage; one-third of the classified MMPs exhibit an alkaline RX(R/K)R consensus cleavage site, rendering them activatable by proconvertases/furin [17, 58] .
Except for MMP-23 (which has a different C-terminal domain) and the two matrilysins MMP-7 and MMP-26, all human MMPs contain an approx. 195-residue C-terminal haemopexin-like (PEX) domain connected covalently to the catalytic domain through a linker of up to 70 residues. In the membrane-type MMPs (MT-MMPs), the polypeptide chains have additional C-terminal tails, which either include a TM helix and terminate with a short cytoplasmic domain [17] , or whose termini act as a glycosylphosphatidylinositol membrane-anchoring signal, which becomes replaced by the glycosylphosphatidylinositol membrane anchor [18] . Most MMPs are glycosylated to different extents and at different sites.
The TIMP family contains four members (TIMPs-1 to -4), which after optimal topological superposition exhibit 41-52% sequence identity (see Figure 3 below; for references, see [7] ). In addition to their inhibitory role, these TIMPs seem to have other functions, such as growth factor-like and antiangiogenic activity (see, e.g., [19, 20] ). The TIMPs, each of which contains between 184 and 194 amino acid residues, form tight 1:1 complexes with MMPs, with K i values down to sub-femtomolar levels [21] . Except for the rather weak interaction between TIMP-1 and most MT-MMPs, the TIMPs do not seem to differentiate much between the various MMPs. In addition, TIMP-1 is capable of binding to proMMP-9 (progelatinase B), TIMPs-2 and -4 can bind to proMMP-2 (progelatinase A), while TIMP-3 binds to both [22] . The complex between the MMP-14 (MT1-MMP) and TIMP-2 acts as a cell-surface- bound 'receptor' for proMMP-2 activation in vivo [23] [24] [25] [26] by presenting the bound proMMP-2 such that an adjacent uninhibited MMP-14 molecule sets a first cut in the pro-domain of MMP-2 (see below), followed by the final activation cleavage by another MMP-2 molecule [27] . MMP-14 is a particularly efficient activator, with its specific 'MT-loop' (Figure 2 ) presumably serving as a specific exosite for proMMP-2 (see below), while MMP-15 (MT2-MMP) seems to act via an alternative, TIMP-2-independent pathway [28] .
Since early 1994, a large number of MMP and TIMP structures have been published, determined mostly by X-ray techniques. The first X-ray crystal structures, determined with the help of 'classical' heavy metal derivatives, were of the catalytic domains (blocked by various synthetic inhibitors) of human fibroblast collagenase (collagenase 1/MMP-1) [29] [30] [31] [32] and human neutrophil collagenase (collagenase 2/MMP-8) [32] [33] [34] (Figure 2 ). At the same time, an NMR structure of the catalytic domain of stromelysin 1/MMP-3 [35] became available. These structures were later complemented by additional X-ray and NMR structures of the catalytic domains of MMP-1, matrilysin/MMP-7 [36] , MMP-3, MMP-8, MMP-14 [37] , collagenase 3/MMP-13 [38] , mouse stromelysin 3/MMP-11 [39] and macrophage metalloelastase/MMP-12 [40, 41] . In 1995 the first X-ray crystal structure of an MMP pro-form (C-terminally truncated prostromelysin 1) was Figure 1 ), -3, -7, -13 and -14 (thin ropes), shown together with a heptapeptide substrate bound productively in the active-site cleft [55] . Strands (sI-sV) and helices (hA-hC) are labelled, and some notable loops are indicated. The catalytic (catZn) and structural (centre and top) zinc ions and the calcium ions (Ca1-Ca3; flanking) are shown as dark grey and light grey spheres respectively. Ct, C-terminus; Nt, N-terminus.
published [42] , and the first structure of a mature full-length MMP (pig fibroblast collagenase 1/MMP-1) [43] was described. In 1999 the structure of full-length proMMP-2 (progelatinase A) [44] was reported (Figure 1) , as was the FN domaindeleted catalytic domain of MMP-2 [45] . Quite recently, the FN domain-deleted catalytic domain [46] and the full-length pro-catalytic domain [47] of MMP-9 were published, and added as new members to the MMP structure zoo (see [48] ).
With regard to the TIMPs, a first preliminary NMR model of human N-TIMP-2 (N-terminal domain of TIMP-2) was presented in 1994 [49] , revealing that the polypeptide framework of the N-terminal part of the TIMPs resembles the so-called OB (oligosaccharide/oligonucleotide-binding)-fold proteins. In 1997, the first structure of a complete TIMP, i.e. human deglycosylated TIMP-1 in complex with the catalytic domain of human MMP-3, was published [50] , and this was followed by the X-ray structure of TIMP-2 in complex with the catalytic domain of MMP-14 [37] . Quite recently, these TIMP complexes were complemented by the proMMP-2-TIMP-2 complex [51] .
In the following, the polypeptide fold, the domains and the structural determinants of the MMP and TIMP structures and their detailed interaction will be described. The MMP nomenclature used is based on the cDNA sequence of (human) fibroblast collagenase-1/MMP-1 as the reference MMP (see [48, 52] ). For the assignment of peptide substrate residues and substrate recognition sites on the proteinase, the nomenclature of Schechter and Berger [53] will be used: P1, P2 etc. and P1Ј, P2Ј etc. indicate the residues in the N-and C-terminal directions respectively from the scissile peptide bond of a bound peptide substrate (analogue); and S1, S2 etc. and S1Ј, S2Ј etc. the equivalent binding sites on the enzyme. TIMP residues will be numbered according to TIMP-1 or TIMP-2.
Structures and mechanisms The MMP catalytic domain
The catalytic domains of the MMPs exhibit the shape of an oblate ellipsoid. In the standard orientation, which in this chapter and in most other MMP papers is preferred for the display of the catalytic domains, a small active-site cleft notched into the flat ellipsoid surface extends horizontally across the domain surface to bind peptide substrates from left to right (Figure 2 ). This cleft, harbouring the catalytic zinc, separates the smaller lower subdomain from the larger upper subdomain.
The upper subdomain (Figure 2) , formed by the first three-quarters of the polypeptide chain, consists of a five-stranded ␤-pleated sheet, which is flanked by three surface loops on its convex side and by two long regular ␣-helices on its concave side embracing a large hydrophobic core. The polypeptide chain starts on the molecular surface of the lower subdomain, where its N-terminal Phe 100 ammonium group, if correctly tailored, can become engaged in a surface-located salt bridge with Asp 250 (see [34, 54] ). The chain turns to the upper domain, passes ␤-strand sI, the amphipatic ␣-helix hA and ␤-strands sII, sIII, sIV and sV, and enters the active-site helix hB (for nomenclature, see Figure 2 ).
Structural basis of matrix metalloproteinases 5
In the classical MMPs, strands sII and sIII are connected by a relatively short loop bridging strand, sI; in the MT-MMPs (MMP-14, -15, -16 and -24), however, this loop is expanded into the spur-like, solvent-exposed MT-specific loop [37] . In all MMPs, strands sIII and sIV are linked via an S-shaped double loop, which is connected via the structural zinc and the first of two to three bound calcium ions to the ␤-sheet. This S-loop extends into the cleft-sided bulge, continuing in the antiparallel edge-strand sIV; this bulge-edge segment is of prime importance for binding of peptide substrates and inhibitors ( Figure  2 ). The sIV-sV connecting loop, together with the sII-sIII bridge, sandwich the second bound calcium. After strand sV, the chain (except in both gelatinases, where it turns towards the 185-residue FN domains, which form the large cloverleaf-like FN domain [44] consisting of three tandem copies of FN modules; see Figure 1) passes the large open sV-hB loop, before entering the active-site helix hB. This helix provides the first (His 218 ) and the second (His 222 ) His residues which, together with His 228 , ligand the catalytic zinc and the catalytic Glu 219 residue between them, all of which represent the N-terminal part of the zinc-binding consensus sequence HEXXHXXGXXH that is characteristic of the metzincin superfamily [8, 9] . This active-site helix stops abruptly at Gly 225 , where the peptide chain bends downwards and descends to present the third zinc-liganding histidine, His 228 , and then runs through a wide right-handed spiral terminating in the 1,4-tight 'Met-turn' (Figure 2) . The chain then turns back to the molecular surface to an almost invariant Pro 238 , forms with a conserved Pro 238 -Xaa-Tyr 240 segment (the S1Ј wall-forming segment) the outer wall of the S1Ј pocket and then runs through the wide specificity loop of slightly variable length and conformation, before it passes the C-terminal ␣-helix hC, which ends with the conserved Tyr 260 -Gly 261 pair.
Specificity determinants
Bounded at the upper rim by the bulge-edge segment and the second part of the S-loop, and at the lower side by the third zinc-liganding imidazole and the S1Ј wall-forming segment, the active-site cleft of all MMPs is relatively flat on the left ('non-primed') side, but carves into the molecular surface at the catalytic zinc and to the right ('primed') side, levelling off again to the surface further to the right (Figure 2) . In unliganded MMPs, the catalytic zinc residing at its centre is co-ordinated by the three imidazole N⑀2 atoms of the three histidines (His 218 , His 222 and His 228 ) and by a fixed water molecule, which simultaneously is within hydrogen-bonding distance of the carboxylate group of the catalytic Glu 219 . In complexes of MMPs with hydroxamate inhibitors, this water molecule is replaced by two oxygen atoms, which, together with the three imidazole nitrogens, ligand the catalytic zinc in a trigonal-bipyrimidal (penta-co-ordinate) manner [33] . As in all other metzincins, the zinc-imidazole ensemble of the MMPs is placed above the distal ⑀-methylsulphur moiety of the strictly conserved Met 236 residue of the Met-turn, which forms a hydrophobic base.
Immediately to the right of the catalytic zinc invaginates the S1Ј specificity pocket, which differs considerably in size and shape among the various MMPs. Of the synthetic inhibitors that have been determined in complex with an MMP, only the Pro-Leu-Gly-hydroxamic acid inhibitor [33, 34] binds to the left-hand subsites (the non-primed subsites S3-S1) alone, antiparallel to the edge strand ('left-side inhibitor'). A few synthetic inhibitors bind across the whole of the active site, while for the majority of synthetic inhibitors studied so far the extended peptide moiety interacts with the primed right-hand subsites ('right-side inhibitors'), inserting between the (antiparallel) bulge-edge segment and the (parallel) S1Ј wall-forming segment of the cognate MMP, causing formation of a three-stranded mixed ␤-sheet (Figure 2 ). An L-configured P1Ј-like side chain can extend into the hydrophobic bottleneck of the S1Ј pocket [55] . This P1Ј-S1Ј interaction is the main determinant of the affinity of inhibitors and the cleavage position of peptide substrates.
With particular dependence on the length and character of residue 214 in the N-terminal part of the active-site helix hB, the size of the S1Ј pocket differs considerably among the MMPs (Figure 2 ). In MMP-1 and MMP-7, for example, the side chains of Arg 214 and Tyr 214 respectively extend into the S1Ј opening, limiting it to a size and shape still compatible with the accommodation of medium-sized P1Ј residues, rendering it less accessible to very large (synthetic) side chains, in agreement with peptide cleavage studies on model peptides. More recently determined MMP-1 structures with synthetic inhibitors show, however, that the Arg 214 side chain can swing out of its normal site, thus also allowing binding of synthetic inhibitors with larger P1Ј side chains [38] . The smaller Leu 214 residue in MMPs-2, -3, -9, -12, -13 and -14 does not block the internal S1Ј 'pore', which extends right through the molecule to the lower surface, i.e. it is more like a long, solvent-filled tube. In spite of its small Leu 214 residue, however, the S1Ј pocket of MMP-8 is of medium size and is closed at the bottom, due to the Arg 243 side chain extending into the S1Ј space from the specificity loop [33] . In MMP-9, the side chain of Arg 424 (corresponding to residue 241 in MMP-1) can also close the end of the pocket [46] .
By replacing the zinc-chelating groups of such peptide left-and right-side inhibitors with a normal peptide bond, a contiguous peptide substrate was constructed to mimic the probable binding geometry of a normal substrate-MMP encounter complex [55] . Accordingly, the peptide substrate chain is aligned in an extended manner with the continuous bulge-edge segment, causing formation of an antiparallel two-stranded ␤-pleated sheet, which on the right-hand side is expanded into a three-stranded mixed parallel-antiparallel ␤-sheet, due to additional alignment with the S1Ј wall-forming segment. A bound peptide substrate (such as the hexapeptide shown in Figure 2 ) can form five and two inter-main-chain hydrogen bonds respectively with the two crossing-over MMP segments. Similar to the reaction mechanism suggested previously for the more distantly related zinc endopeptidase thermolysin [56] , the MMPcatalysed cleavage of the scissile peptide bond will probably proceed via a general-base mechanism [55] .
The MMP pro-domain
Currently, the only proMMP structures known are those of C-terminally truncated proMMP-3 [42] and proMMP-9 [47] , and of full-length proMMP-2 (Figure 1 ) [44] . The pro-domain peptide has an egg-like shape, attached with its Structural basis of matrix metalloproteinases 7
rounded-off side to the active site of the catalytic domain. It consists essentially of three mutually perpendicularly packed ␣-helices and an almost invariant Pro 90 -Arg-Cys-Gly-Val-Pro-Asp 96 'cysteine switch' loop running through the active-site cleft in the opposite direction to bound substrates, extending into the catalytic domain. From Pro 107 onwards, the polypeptide chains of the three proMMPs are in register with those of the mature (i.e. activated) MMPs. In MMP-11, MMP-28 and the six MT-MMPs, the connecting segment between the switch loop of the pro-chain and the N-terminus of the mature MMP is elongated further, by up to 22 residues (MMP-28), with the prodomain-chain terminating in an Arg-Xaa-Arg/Lys-Arg sequence typical of cleavage by furin-like convertases [17] . The intracellular cleavage of these MMPs in the trans-Golgi network results in expression of the active enzymes at the cell surface [18, 57] .
The proteolytic activation of these 'classical' proMMPs (see [54] ) seems to proceed via a stepwise mechanism. Some early cleavages occurring in the flexible, exposed helix 1-helix 2 loop (the 'bait') might not only expose the hydrophobic core of the pro-domain, but also destabilize this domain, thus exposing other (downstream) cleavage sites and weakening and finally disrupting the Cys-catalytic-zinc interaction. This will lead eventually to liberation and increased flexibility of the Xaa 99 -Phe/Tyr 100 activation cleavage peptide bond (as originally predicted by the 'cysteine switch hypothesis' [16] ).
The PEX domain
Except for MMPs-7, -23 and -26, all vertebrate/human MMPs are expressed with a C-terminal PEX domain. Some of these PEX domains have been shown to be involved in substrate recognition and to confer substrate specificity, most dramatically in the collagenase subfamily, where the ability to cleave native triple-helical collagen is associated with the covalently bound PEX domain (for references, see [10, 25] ). The PEX domains exhibit the structure of a four-bladed ␤-propeller of pseudo four-fold symmetry [43] (see Figure 1 ). The polypeptide chain is organized essentially in four ␤-sheets (blades), I-IV, which are arranged almost symmetrically around a central axis in consecutive order. Each propeller blade is twisted and consists of four antiparallel ␤-strands connected in a W-like topology. The first, innermost strands of all four blades enter the propeller at one site and run almost parallel to one another along the propeller axis, forming a central funnel-shaped tunnel, which opens slightly towards the exit and often accommodates some ions. The fourth strands of blades II and III are interrupted by characteristic ␤-bulges, which allow these strands to remain in-phase with the antiparallel third strands, in spite of the overall sheet curvature. In all four blades, the outer segments loop around the periphery of the disc and end in short helical segments. The Cterminus of the blade IV helix is connected to the entering strand of blade I via a single disulphide bridge, rigidifying the whole domain.
In the two full-length MMP structures available [43, 44] , the catalytic domain and the PEX domain make non-covalent contacts only along small domain edges, with the outermost strand of the first blade of the PEX domain propeller contacting the C-terminal helix hC of the catalytic domain (see Figure 1 ). The Pro-rich linker between the two domains bulges backwards and runs in a loose manner, antiparallel to helix hC, before it joins the PEX moiety. The linkers of the four collagenases are shortest of all MMPs, which might add to the rigid juxtaposition of their catalytic and PEX domains. The interdomain linkers are considerably longer, however, in the MT-MMPs, possibly giving more freedom to the relative placement of the catalytic and PEX domains. MMP-9 exhibits the longest interdomain linker, which is heavily O-glycosylated and has been predicted to be type-V-collagen-like (for references, see [59] ).
Chimaeric constructs made in order to elucidate the structural features defining the triple-helicase specificity of collagenases have shown that the catalytic domain, the hinge and the PEX domain possess important determinants, and that all three must be arranged correctly to act in concert to confer helicase specificity (for references, see [48] ). The Glu(Asn) 209 -Tyr-Asn-Leu segments of MMPs-1 and -8 respectively, which precede the active-site helix and are located in the corridor connecting the catalytic domain and the PEX domain, seem to form a critical exosite for triple-helical collagen substrates [60, 61] . Intriguingly, Tyr 209 in MMPs-1 and -8 is preceded by a cis-bond, distinguishing these more powerful type I and II collagenases from other collagen-degrading MMPs, such as MMP-2, MMP-13 and MMP-14 (for a more detailed discussion, see [61] ). Triple-helical collagen substrates thus may bind into the active-site cleft of the cognate MMP with partial unwinding from P3 to P3Ј, bend at the 209 exosite, and interact with blade II of the PEX domain [62] . Other potential triple-helicase mechanisms have recently been discussed in detail by Overall [10] .
TIMP complexes and the proMMP activation complex
The wedge-shaped TIMP molecules consist of an N-terminal segment, an all-␤-structure N-terminal part, an all-helical centre, and a C-terminal ␤-turn structure [50] . The N-terminal half, consisting essentially of a closed fivestranded ␤-barrel, and the C-terminal half of the polypeptide chain form two opposing subdomains (Figure 3) . The TIMP edge is formed by five sequential, seperate chain segments, namely the extended N-terminal segment Cys 1 -Pro 5 and two flanking loops on either side provided by the N-and C-terminal parts. Particularly remarkable features of TIMP-2 are the quite elongated sA-sB ␤-hairpin loop and the much longer negatively charged flexible C-terminal tail [37] .
In complexes with MMPs, the wedge-shaped TIMPs bind with their edge into the entire length of the active-site cleft of their cognate MMPs [37, 50] , with some rigidification of the participating loops [63] [64] [65] . The first five TIMP residues, Cys 1 -Pro 5 , bind to the MMP active-site cleft in a substrate-or productlike manner, i.e. similar to the way in which the P1, P1Ј, P2Ј, P3Ј and P4Ј residues of peptide substrates insert between the bulge and the wall-forming segments, forming five intermolecular inter-main-chain hydrogen bonds. Cys 1 is located directly above the catalytic zinc, with its N-terminal ␣-amino nitrogen and its carbonyl oxygen atoms co-ordinating the catalytic zinc together with the three imidazole rings from the cognate MMP. The Thr/Ser side chain of the second TIMP residue extends, similar to the side chain of a peptide substrate P1Ј residue, into the S1Ј pocket of the cognate MMP, without filling this pocket properly [7] .
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It has been known for some time that MMP-14, via a bound TIMP-2 molecule, fixes a proMMP-2 molecule through its PEX domain, presenting the Asn 37 -Leu 38 scissile peptide bond to a second, non-inhibited MMP-14 molecule [23, 24, 26] . Participation of the negatively charged C-terminal tail of TIMP-2 had been demonstrated [66, 67] , and the binding site for TIMP-2 on proMMP-2 could be narrowed down to the junction of blades III and IV on the peripheral rim of the MMP-2 PEX domain by site-directed mutagenesis of surface-located alkaline residues [68] . The recent crystal structure of the proMMP-2-TIMP-2 complex [51] shows these TIMP-2-PEX2 interactions at atomic resolution. The two components interact via mixed hydrophobic/polar interfaces, essentially through two distinct but adjacent binding regions, formed by (i) strands 3 and 4 of blade IV with the central area of the C-terminal domain of TIMP-2, and (ii) strands 2-4 of blade III with the C-terminal tail of TIMP-2.
On the basis of the experimental MMP-14-TIMP-2 [37] and proMMP-2-TIMP-2 [51] structures, and using other information, modelling of the functional quarternary proMMP-2 activation complex can be attempted ( Figure  3 Shown is a suggested model of the quarternary complex formed by one membrane-bound full-length 'receptor' MMP-14 molecule (yellow), inhibited by a TIMP-2 molecule (blue) [37] , whose C-terminal part binds to the PEX2 domain proMMP-2 ligand (red) [51] . This complex in turn presents its scissile peptide bond to another membrane-bound full-length MMP-14 activator (green). See the text for further details.
the basis of secondary structure predictions should, besides a short ␤-strand, comprise mainly non-classifiable secondary structure elements), a 20-residue ␣-helical TM14 domain perforating the membrane, and a 26-residue cytoplasmic domain (Figure 3 ). The orientation and position of the PEX14 domain relative to the catalytic domain must (due to a considerable clash with the PEX2 domain of MMP-2 in the ternary/tertiary complex; see below) differ substantially from that observed in the full-length MMPs-1 and -2, which would be facilitated by the much longer catalytic domain-PEX domain linker of MMP-14. TIMP-2 docks to this 'receptor' MMP-14, as observed in the MMP-14-TIMP-2 structure, with its C-terminal negatively charged tail stretched, as observed in the proMMP-2-TIMP-2 structure. The proMMP-2 ligand will dock with this TIMP-2, as observed in the latter complex. The primary cleavage site around Asn 37 -Leu 38 in proMMP-2 is not susceptible to MMPs in its usual conformation. Thus it must (facilitated by the extremely high temperature factors of the primed-side residues) unfold and adapt to allow another MMP-14 molecule to attack the Asn 37 -Leu 38 bond, while the relatively rigid Cys 31 -Cys 36 non-primed-side loop must rearrange. Modelling trials show that the catalytic domain of this second MMP-14 could embrace the (quite flexible and plastic) pro-domain of proMMP-2 by virtue of its double S-loop, its exposed sIV-sV loop and its MT-specific loop, thus constraining the position and orientation of the catalytic domain of MMP-14. The PEX14 domain plus the adjacent TM domain and the cytoplasmic domain are arranged such that the two PEX14 domains (i.e. one from each MMP-14 molecule) form a homodimer, similar to that observed for the crystalline but non-covalent PEX9 dimer [69] , so that the two TM domains and two cytoplasmic domains of the MMP-14 molecules will also stay together. Such homophilic complex formation of membrane-bound MMP-14 has been suggested by the homodimerization of PEX14 and the functional dependence of activation of MMP-14 on possession of the correct PEX14 domain [70] , and by the importance of oligomerization through the cytoplasmic domains [71, 72] .
